[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vertex: The Cystic Fibrosis Franchise Meets Its First Real Comps Test

Vertex Pharmaceuticals (NASDAQ: VRTX) reports second-quarter 2026 earnings after the close on August 3, with analysts expecting continued momentum from its cystic fibrosis franchise and growing contributions from newer therapies. The biotech has delivered four consecutive earnings beats, but investors will be scrutinizing whether the company can sustain its growth trajectory amid increasing competition and pipeline execution questions. With the stock trading near recent highs and options pricing a significant post-earnings move, this report could set the tone for the second half of 2026.

Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, with its dominant cystic...

Fundamentals

See More
  • Market Capitalization, $K 121,090,360
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.29
  • Price/Sales 10.19
  • Price/Cash Flow 27.41
  • Price/Book 6.33

Options Overview Details

View History
  • Implied Volatility 41.68% (+2.22%)
  • Historical Volatility 30.14%
  • IV Percentile 96%
  • IV Rank 81.15%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 5) 24.98 (5.24%)
  • Put/Call Vol Ratio 1.76
  • Today's Volume 2,837
  • Volume Avg (30-Day) 3,308
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 51,913
  • Open Int (30-Day) 47,618
  • Expected Range 452.12 to 502.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.30
  • Number of Estimates 5
  • High Estimate $4.46
  • Low Estimate $4.01
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +7.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
465.00 +2.60%
on 07/23/26
533.67 -10.60%
on 07/07/26
-19.63 (-3.95%)
since 06/30/26
3-Month
412.27 +15.73%
on 05/05/26
533.67 -10.60%
on 07/07/26
+49.72 (+11.63%)
since 04/30/26
52-Week
362.50 +31.61%
on 08/11/25
533.67 -10.60%
on 07/07/26
+7.94 (+1.69%)
since 07/30/25

Most Recent Stories

More News
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

VRTX : 477.10 (-0.95%)
Vertex: The Cystic Fibrosis Franchise Meets Its First Real Comps Test

Barchart Research What to Expect from VRTX Earnings VRTX Generated July 31, 2026 Current Price $477.10 EPS Estimate $$4.30 Consensus Rating Moderate Buy Average Move 6.21% Vertex: The Cystic Fibrosis Franchise...

VRTX : 477.10 (-0.95%)
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers...

ABCL : 5.71 (+0.35%)
VRTX : 477.10 (-0.95%)
3 Healthcare Stocks with Competitive Advantages

3 Healthcare Stocks with Competitive Advantages

VRTX : 477.10 (-0.95%)
ZTS : 77.29 (+1.66%)
ALHC : 14.85 (-20.20%)
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question

1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question

MDLZ : 62.31 (-1.22%)
VRTX : 477.10 (-0.95%)
WDAY : 160.34 (+1.41%)
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

XLV : 162.55 (-0.59%)
$SPX : 7,489.72 (+0.70%)
VRTX : 477.10 (-0.95%)
1 Momentum Stock to Research Further and 2 Facing Headwinds

1 Momentum Stock to Research Further and 2 Facing Headwinds

HNI : 45.01 (+3.28%)
CALY : 18.46 (-0.38%)
VRTX : 477.10 (-0.95%)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals...

CRNX : 83.52 (-0.13%)
VRTX : 477.10 (-0.95%)
Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

CRSP : 47.99 (-0.93%)
CRNX : 83.52 (-0.13%)
VRTX : 477.10 (-0.95%)
AI stocks sink and drag markets lower worldwide

The roller-coaster ride for AI stocks snapped back down and dragged Wall Street lower

NVDA : 200.75 (+2.93%)
AAPL : 308.91 (-7.35%)
AVGO : 389.28 (+0.37%)
$SPX : 7,489.72 (+0.70%)
CRNX : 83.52 (-0.13%)
MU : 823.03 (-5.90%)
VRTX : 477.10 (-0.95%)
RIVN : 15.22 (-9.57%)
$IUXX : 28,274.20 (+0.60%)
WULF : 17.66 (-0.90%)
SPCX : 108.37 (-3.41%)
INTC : 90.20 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 492.69
2nd Resistance Point 486.68
1st Resistance Point 481.89
Last Price 477.10
1st Support Level 471.09
2nd Support Level 465.08
3rd Support Level 460.29

See More

52-Week High 533.67
Last Price 477.10
Fibonacci 61.8% 468.28
Fibonacci 50% 448.08
Fibonacci 38.2% 427.89
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.